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REPLY
We thank Drs. Almeda and Schaer for their interesting comments.
We have previously reported that ostial in-stent restenotic lesions
treated with intracoronary radiation have equivalent clinical out-
comes to nonostial irradiated in-stent restenotic lesions and have
significantly reduced recurrent restenosis compared to in-stent
restenotic ostial lesions treated with conventional percutaneous
interevention alone (1). We did not find that postprocedural
minimal luminal diameter correlated with subsequent failure,
although smaller vessels (based on reference vessel diameter) have
higher restenosis rates. Intracoronary radiation therapy reduces
angiographic restenosis in all sized vessels, with the effect seen
predominantly in small vessels (2.5 mm) (2). In the current
analysis, these factors did not influence clinical outcomes.
The initial enthusiasm for the cutting balloon as an interven-
tional strategy for in-stent restenosis has not been supported by
reduced event rates in clinical trials. There is no evidence showing
the cutting balloon to be superior over conventional angioplasty
with adjunctive intracoronary radiation.
Our ongoing analysis suggests the time to first target vessel
revascularization in the majority of patients is between 6 to 12
months, suggesting there is a “delay” in recurrent restenosis
compared to conventional angioplasty. Recurrent restenosis be-
yond 12 months has been infrequent in the majority of published
Washington Radiation for In-stent restenosis Trial (WRIST)
series.
The overall use of glycoprotein (GP) IIb/IIIa inhibitors in the
current analysis was 22% and did not influence clinical outcomes.
Integrilin WRIST was a randomized trial addressing whether the
treatment of eptifibatide (small-molecule competitive GPIIb/IIIa
inhibitor) would improve both the procedural and the long-term
outcomes in patients undergoing treatment for in-stent restenosis
with intracoronary radiation therapy. That study (submitted for
publication) did not detect differences in major clinical events with
use of GPIIb/IIIa inhibitors. However, at any end point of the
study there was nonsignificant reduction of creatine phosphokinase
release in the eptifibatide group when compared to control, and
these findings may stimulate a larger study to detect benefit of
GPIIb/IIIa inhibitors in the setting of intracoronary radiation
therapy.
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Clinical Decision Making
on Statin Drug Interactions
Recent comments by Dr. Hansten (1) regarding drug-drug inter-
actions and myopathy risk with statins provide important addi-
tional information to guidelines issued last year on the use of these
agents (2). The metabolism of statins is complex, with extensive
conversion between the lactone, open-acid, and glucuronidated
forms as well as other less common metabolites (3,4). As Dr.
Hansten noted, pravastatin undergoes the least cytochrome P450
(CYP)-mediated metabolism and is therefore the least susceptible
to interactions with drugs that inhibit this system (5–7). Also,
simvastatin and lovastatin are more prone to interactions with
CYP inhibitors, owing in part to the fact that these agents are
administered as the more lipophilic lactone form, whereas all other
agents (including cerivastatin) are administered as the open-acid
form (3,8). And though these findings are important, I believe they
should be incorporated into clinical practice with several important
caveats in mind.
First, the kinetics of statins is more complex than just their
hepatic handling. The 5-fold increase in pravastatin area under the
curve (AUC) induced by cyclosporine is now widely recognized to
be the result of inhibition of the adenosine triphosphate-binding
cassette transporter P-glycoprotein (Pgp) in the gut wall (9,10).
Inhibition of Pgp allows greater absorption of pravastatin, thereby
increasing its systemic bioavailability, which is already four-fold
higher than lovastatin and simvastatin (3,8). Other inhibitors of
Pgp include erythromycin, quinidine, amiodarone, and verapamil
(11–13).
Second, the greatest risk of myopathy with statins occurs when
they are used with other lipid-lowering agents and is the result of
pharmacodynamic, as well as pharmacokinetic, interactions
(3,8,10,14). In this regard, pravastatin carries an increased risk
similar to the other agents (5,15,16). And though case reports of
myopathy are more common with lovastatin and simvastatin, four
published studies of 39,285 patients and over 160,000 patient-
years of therapy have failed to find a greater risk for these agents
compared to placebo (14,17,18).
Finally, the primary aim of statins is to reduce cardiovascular
(CV) events. The recent failure of 40 mg of pravastatin to
significantly reduce CV events in the ALLHAT-LLT trial (19)
stands in contrast to the recent findings of a robust benefit of 40
mg of simvastatin in the HPS trial (17). It is also notable that while
a lower threshold low density lipoprotein (LDL) of 125 mg/dl was
found for the beneficial effects of pravastatin in both the CARE
and LIPID trials (20,21), no such threshold finding for simvastatin
was found in the 4S trial (18). In fact, in the HPS trial, CV events
were significantly reduced by simvastatin in the 3,500 participants
with a baseline LDL below 100 mg/dl (mean 97 mg/dl) (17).
Thus, though interactions should always be considered when
prescribing multiple medications, until clearer mechanisms of both
benefit and risk are elucidated for statins, outcomes data remain
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